Momelotinib (CYT387)

Catalog No.S2219 Synonyms: LM-1149 , CYT11387

Momelotinib (CYT387) Chemical Structure

Molecular Weight(MW): 414.46

Momelotinib (CYT387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. Phase 3.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 14 Publications

4 Customer Reviews

  • IL-6- supported INA-6 cells were treated with the JAK inhibitors ruxolitinib (Rux; 10 nM) or CYT387 (CYT; 50 nM) for 1 hour and assessed for inhibition of STAT3 phosphorylation by immunoblotting.

    J Clin Invest 2014 10.1172/JCI69094. Momelotinib (CYT387) purchased from Selleck.

  • HEL cells, expressing the Jak2-V617F mutant and showing constitutive activation of STAT5, were treated for 3h with Cyt387 at the indicated concentrations. Cells lysates were then subjected to SDS-PAGE and Western blotting. The Blots were detected with the indicated fluorescent antibodies using the LI-COR Biosciences detection system.

    2014 Dr. Claude Haan and Catherine Rolvering from University of Luxembourg. Momelotinib (CYT387) purchased from Selleck.

  • Shown are WT pan T cells (both CD4＋and CD8＋ T cells; CD4－T cells are CD8＋T cells) after drug treatment.

    Blood 2012 120(19), 4093-103. Momelotinib (CYT387) purchased from Selleck.

  • Percent pJAK2 and pSTAT5 for each cell line and inhibitor condition are displayed relative to mean basal phosphoprotein levels of control CD45+14+18+ myeloid cells. Experiments were performed in triplicate. Statistical analyses were performed with ANOVA and the Dunnett post-test for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

    Leukemia, 2018, doi:10.1038/s41375-018-0169-y. Momelotinib (CYT387) purchased from Selleck.

Purity & Quality Control

Choose Selective JAK Inhibitors

Biological Activity

Description Momelotinib (CYT387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. Phase 3.
Targets
JAK1 [1]
(Cell-free assay)		 JAK2 [1]
(Cell-free assay)		 JAK3 [1]
(Cell-free assay)
11 nM 18 nM 155 nM
In vitro

CYT387 inhibits the proliferation of parental Ba/F3 cells (Ba/F3-wt) stimulated by IL-3 with IC50 of 1400 nM. Furthermore, CYT387 also causes the inhibition of cell proliferation in cell lines constitutively activated by JAK2 or MPL signaling, including Ba/F3-MPLW515L cells, CHRF-288-11 cells and Ba/F3-TEL-JAK2 cells with IC50 of 200 nM, 1 nM and 700 nM, respectively. In addition, CYT387 has been shown to inhibit erythroid colony growth in vitro from JAK2V617F-positive PV patients with similar potency with IC50 of 2μ-4 μM. [1] A recent study shows that CYT387 inhibits PI3K/AKT and Ras/MAPK signaling induced by IL-6 and IGF-1. Moreover, CYT387 induces apoptosis as a single agent and synergizes with the conventional anti-MM therapies bortezomib and melphalan in primary multiple myeloma (MM) cells. [2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human SET2 cells MYnQdo9tcW[ncnH0bY9vKGG|c3H5 NHfxZ4w4OiCq NHKx[IJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPFWFIh[2WubIOg[ZhxemW|c3nu[{BLSUt{IG[2NVdHKG23dHHueEBscW6jc3WgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR|UxRTBwMkOyJO69VQ>? Mnv2NVk4PjJ{M{i=
mouse BAF3 cells MYXQdo9tcW[ncnH0bY9vKGG|c3H5 MWe3NkBp M4TCRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDlfJBz\XO|aX7nJHRGVC2MQVuyJItqdmG|ZTDh[pRmeiB5MjDodpMh[nliYXzhcYFzKGKudXWgZZN{[Xl? NFznN2UyQTd4MkKzPC=>
human HEL 92.1.7 cells NGXQN3lRem:uaX\ldoF1cW:wIHHzd4F6 MVe3NkBp M4OwfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFXMJFkzNjFwNzDj[YxteyCneIDy[ZN{cW6pIFrBT|IhXjZzN1[gcZV1[W62IHvpcoF{\SCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUC9NU45ODRizszN MlTDNVk4PjJ{M{i=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26625308     


RCC cell lines were treated for 24 hours with the indicated concentrations of CYT387, and lysates were probed with the indicated antibodies. Actin was used as loading control.

p-Src / Src ; 

PubMed: 26625308     


RCC cells were treated with 100 nM of dasatinib and 2 μM of CYT387, alone, in combination or DMSO for 24 hours and lysates were probed with the indicated antibodies.

26625308
Immunofluorescence
p62 / pS6 ; 

PubMed: 29138276     


ACHN cells were grown on coverslips, treated with CYT387 for 24 h, and stained p62 and p-S6. 

29138276
Growth inhibition assay
Cell viability; 

PubMed: 20385788     


Ba/F3-EpoR parental (cultured in media supplemented with 3 U/mL erythropoietin) or Ba/F3-EpoR-JAK2(V617F) cells (cultured in the absence of exogenous cytokines) were plated in 96-well plates over a dose gradient of CYT387 for 3 days at which point cell viability was measured with an MTS tetrazolium salt assay. Values represent mean ± SEM. n = 3; *P < .05.

20385788
In vivo In a murine MPN model, CYT387 normalizes white cell counts, hematocrit, spleen size, and restores physiologic levels of inflammatory cytokines. [3]

Protocol

Kinase Assay:[1]
- Collapse

Cell-free kinase activity assays:

Glutathione-S-transferase (GST)-tagged JAK kinase domains expressed in insect cells are purified before use in a peptide substrate phosphorylation assay. Assays are carried out in 384-well optiplates using an Alphascreen Protein Tyrosine Kinase P100 detection kit and a PerkinElmer Fusion Alpha instrument.
Cell Research:[1]
- Collapse
  • Cell lines: Ba/F3, Ba/F3-JAK2V617F and Ba/F3-MPLW515L cells
  • Concentrations: 0 to 10 μM
  • Incubation Time: 72 hours
  • Method: Ba/F3 cells expressing JAK2V617F (Ba/F3-JAK2V617F) and MPLW515L (Ba/F3-MPLW515L) mutants, as well as CHRF-288-11 (JAK2T875N) and CMK (JAK3A572V) cells are used. The TEL/JAK2 and TEL/JAK3 fusions are generated and introduced into Ba/F3 murine cells. The TEL/JAK2- or TEL/JAK3-transfected cells are cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS). Ba/F3 wild-type cells are cultured in RPMI containing 10% FCS supplemented with 5 ng/mL murine IL-3. Proliferation is measured using the Alamar Blue assay after incubating for 72 hours at 37 °C with 5% CO2(Only for Reference)
Animal Research:[3]
- Collapse
  • Animal Models: Balb/c mice are transplanted with bone marrow transduced with a JAK2V617F retrovirus.
  • Formulation: CYT387 is dissolved in NMP (120 mg/mL final; 1-methyl-2-pyrrolidinone, Chromasolv Plus). Subsequently, the CYT387/NMP mix is diluted with 0.14 M Captisol to a concentration of 6 mg/mL and further diluted with 0.1M Captisol to a final concentration of 4 mg
  • Dosages: ≤50 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 74 mg/mL (178.54 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing. 		30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 414.46
Formula

C23H22N6O2
CAS No. 1056634-68-4
Storage powder
in solvent
Synonyms LM-1149 , CYT11387

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

JAK Signaling Pathway Map

JAK Inhibitors with Unique Features

Related JAK Products

  • FLLL32 New

    FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM.

  • Cerdulatinib (PRT062070, PRT2070) New

    Cerdulatinib (PRT-062070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.

  • Ruxolitinib (INCB018424)

    Ruxolitinib (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3.

  • Tofacitinib (CP-690550) Citrate

    Tofacitinib citrate (CP-690550 citrate) is a novel inhibitor of JAK with IC50 of 1 nM, 20 nM and 112 nM against JAK3, JAK2, and JAK1, respectively.

  • Tofacitinib (CP-690550,Tasocitinib)

    Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1.

  • AZD1480

    AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1.

  • Fedratinib (SAR302503, TG101348)

    Fedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Phase 2.

  • WP1066

    WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells; shows activity to JAK2, STAT3, STAT5, and ERK1/2 not JAK1 and JAK3. Phase 1.

    Features:Similar to its parent compound AG490, WP1066 inhibits the phosphorylation of JAK2, but unlike AG490, WP1066 also degraded JAK2 protein.

  • Baricitinib (LY3009104, INCB028050)

    Baricitinib (LY3009104, INCB028050) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM in cell-free assays, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Phase 3.

Tags: buy Momelotinib (CYT387) | Momelotinib (CYT387) supplier | purchase Momelotinib (CYT387) | Momelotinib (CYT387) cost | Momelotinib (CYT387) manufacturer | order Momelotinib (CYT387) | Momelotinib (CYT387) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID